New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:48 EDTISISIsis CEO says APOC3 data 'really exciting,' NY Times reports
Following the publication of new studies that independently identified mutations in the APOC3 gene that protect against heart attacks, the CEO of Isis Pharmaceuticals, Stanley Crooke, whose company is developing a drug that counteracts the gene, said, "Trust me, these data are really exciting" and called the product "the most important drug" in the company's pipeline, according to The New York Times. Experts see the findings leading to a push to develop drugs that mimic the effect of the mutations, but caution that drug development takes years and that there are no guarantees that new treatments will succeed, the report noted. Shares of Isis are up 4% in pre-market trading following the study publications. Reference Link
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 20, 2014
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
November 14, 2014
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use